Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study

BACKGROUND: Given the incurable nature of multiple myeloma (MM), efforts are made to improve the efficacy of anti‐CD38 monoclonal antibodies via combinations with other potentially synergistic therapies. This Phase 1/2 trial (NCT03194867) was designed to determine whether cemiplimab (anti‐PD‐1) enha...

Descripción completa

Detalles Bibliográficos
Autores principales: Lesokhin, Alexander, LeBlanc, Richard, Dimopoulos, Meletios A., Capra, Marcelo, Carlo‐Stella, Carmelo, Karlin, Lionel, Castilloux, Jean‐Francois, Forsberg, Peter, Parmar, Gurdeep, Tosikyan, Axel, Pour, Ludek, Ribrag, Vincent, Ribolla, Rossella, Abdallah, Al‐Ola, Le Roux, Nadia, Dong, Liyan, van de Velde, Helgi, Mayrargue, Laurent, Lépine, Lucie, Macé, Sandrine, Moreau, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225222/
https://www.ncbi.nlm.nih.gov/pubmed/36866838
http://dx.doi.org/10.1002/cam4.5753

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225222/
https://www.ncbi.nlm.nih.gov/pubmed/36866838
http://dx.doi.org/10.1002/cam4.5753

Ejemplares similares